NCT00006136View on ClinicalTrials.gov

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 1999

Conditions

Beta-Thalassemia

Interventions

DRUG

arginine butyrate

DRUG

epoetin alfa

Trial Locations (7)

10029

Mount Sinai School of Medicine, New York

20892

Clinical Hematology Branch, Bethesda

94609

Children's Hospital of Oakland, Oakland

06520-8028

Yale Comprehensive Cancer Center, New Haven

02118

Boston University School of Medicine, Boston

Cancer Research Center, Boston

W1W 7EJ

University College London, London

All Listed Sponsors

lead

Boston University

OTHER

NCT00006136 - Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia | Biotech Hunter | Biotech Hunter